Why the study?
Does the combination of a thromboxane receptor antagonist and a thromboxane synthase inhibitor inhibit platelet aggregation and prolong bleeding time more than either drug alone in healthy volunteers?
Does the combination of a thromboxane receptor antagonist and a thromboxane synthase inhibitor inhibit platelet aggregation and prolong bleeding time more than either drug alone in healthy volunteers?
Combined thromboxane synthase inhibition and receptor antagonism provides stronger inhibition of platelet aggregation than either drug alone, suggesting endogenous antiaggregatory prostaglandins contribute to hemostasis impairment.
No takes yet. Share an insight, caveat, or question.
Supports testing combined thromboxane blockade in patients; extends mechanistic evidence on prostaglandin redirection in hemostasis.
Gresele et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: